Europe’s biotech start-up environment has been boosted by prominent venture capital groups launching new funds, and this investor enthusiasm looks to be sustainable. As the second half of 2018 got underway, Abingworth, which announced it had raised $315 million for its 12th fund ABV VII, said it intends to allocate about 50% of that sum in Europe, while Forbion, which announced a first close of Forbion IV at €275 million, is earmarking up to 80% of its money for European opportunities.
These two closings add to other prominent new fund launches by European venture capitalists during 2018. In February, Andera Partners...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?